HanchorBio Unveils Promising HCB101 Results at FACO 2025
In a significant breakthrough for cancer treatment, HanchorBio Inc. presented groundbreaking findings during the International Conference of the Federation of Asian Clinical Oncology (FACO 2025). The company showcased results from its ongoing Phase 1 study of HCB101, an innovative SIRP?-engineered Fc fusion protein, which revealed notable safety and early signs of antitumor activity in patients with advanced cancers.
Key Findings from HCB101
Dr. Fangling Ning, from the Affiliated Hospital of Binzhou Medical University, reported that HCB101 is emerging as a potential game-changer in targeting the CD47-SIRP? axis, demonstrating encouraging efficacy signals in both solid tumors and lymphomas. One of the standout features of this novel therapy is its ability to mitigate common side effects like anemia and cytopenias that often plague patients receiving prior treatments in this category.
Study Highlights
The presentation detailed findings from a multinational, first-in-human trial (NCT05892718) that has enrolled 49 patients across various dosing levels. Here are the pivotal updates that were highlighted:
- Safety Profile: The study noted a favorable safety profile where only a single case of dose-limiting toxicity (DLT) was recorded, specifically, a transient Grade 3 thrombocytopenia at a dose of 2.56 mg/kg.
- Consistent Receptor Occupancy: Patient dosing demonstrated greater than 90% receptor occupancy at doses starting from 1.28 mg/kg.
- Encouraging Antitumor Activity: Two confirmed partial responses were observed in patients with head and neck squamous cell carcinoma and non-Hodgkin lymphoma, along with sustained disease control in several other cases.
Comments from HanchorBio Leadership
Scott Liu, Ph.D., the Chairman, CEO, and Founder of HanchorBio, expressed optimism regarding the company's innovative FBDB™ platform that is shaping the future of immunotherapy. He remarked on the excellent safety findings and initial positive responses from patients who had undergone extensive previous treatments. This trial not only highlights HCB101's safety and pharmacokinetics but also lays the groundwork for combination therapies that could significantly impact various tumor types.
Introduction to HCB101
HCB101 is touted as a next-generation therapeutic agent developed with sophisticated techniques, positioning it as a 3.5th-generation affinity-optimized SIRP?-Fc fusion protein. Its unique design, developed on the proprietary FBDB™ platform, focuses on selective targeting of CD47 while minimizing interactions with red blood cells to avoid complications like anemia and thrombocytopenia. Here are some of its key defining features:
- Enhanced Safety: A cytopenia-sparing profile with no dose-limiting toxicities noted thus far, confirming a broad therapeutic window.
- Robust Immune Activation: It has been engineered to improve antibody-dependent cellular phagocytosis and maintain a transfer from innate to adaptive immunity.
- Wide Tumor Applicability: Preclinical models indicate significant activity across more than 80 models, with early clinical effectiveness noted in multiple cancer types.
- Clinical Translation: As a monotherapy, HCB101 has provided durable disease control and a perfect confirmed partial response rate in specific cancer combinations, showcasing its potential to exceed existing treatment benchmarks.
About the Ongoing Clinical Trial
The HCB101 clinical trial (HCB101-101; NCT05892718) represents a comprehensive effort to understand the effects of HCB101 on various solid tumors and advanced non-Hodgkin lymphoma. This ongoing study, conducted at multiple sites, is utilizing a stepwise dose adjustment strategy to ensure participant safety while optimizing therapeutic outcomes. Primary goals include assessing safety and tolerability, alongside secondary endpoints that measure pharmacokinetics and antitumor efficiency. Preliminary data reflects a solid safety profile and promising pharmacodynamic effects.
About HanchorBio
HanchorBio, with its headquarters in Taipei, Shanghai, and the San Francisco Bay Area, is pioneering advanced immuno-oncology therapies. The expertise of its dedicated team revolves around biologics discovery and development, aiming to transform cancer treatment paradigms. Their commitment is manifest in their Fc-based designer biologics platform, which effectively integrates multiple targeting mechanisms and enhances immune response capabilities to overcome contemporary challenges in cancer therapy.
Frequently Asked Questions
What is HCB101?
HCB101 is an innovative SIRP?-engineered Fc fusion protein being developed by HanchorBio, demonstrating promise in cancer therapy by targeting the CD47-SIRP? axis.
What were the results of the Phase 1 study presented?
The Phase 1 study revealed a favorable safety profile, consistent receptor occupancy, and encouraging antitumor activity in patients.
Where was the FACO 2025 conference held?
The FACO 2025 conference took place in Shanghai, providing a platform for HanchorBio to present its findings.
Who is overseeing the clinical trials for HCB101?
The ongoing clinical trials for HCB101 are being conducted by HanchorBio across multiple international sites, ensuring thorough assessment and safety.
What is the next step for HCB101's development?
Following the promising Phase 1 results, HanchorBio plans to initiate combination trials to further explore the therapeutic potential of HCB101.
